FAGR Fagron SA

Rob ten Hoedt non-executive director of Fagron

Rob ten Hoedt non-executive director of Fagron

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 20 December 2019

Rob ten Hoedt non-executive director of Fagron

The Board of Directors of Fagron has decided, following the advice of the nomination and remuneration committee, to co-opt Rob ten Hoedt as non-executive and independent director of Fagron.

Koen Hoffman, chairman of the Board of Directors: “We are pleased to welcome Rob ten Hoedt on the Board of Directors. With his broad and international management experience and extensive background in the medical technology industry, he will be a valuable addition to our Board.”

The appointment of Mr. Ten Hoedt is subject to approval by the next general meeting of shareholders of Fagron.

Rob ten Hoedt (1960)

Rob ten Hoedt is President for Europe, the Middle East and Africa (EMEA) and member of the Executive Committee of Medtronic (). Ten Hoedt has held numerous international sales, marketing and general management positions in the medical technology industry and has been with Medtronic since 1991. He is also chairman of the board of Medtech Europe, the European trade association for the medical technology industry. Ten Hoedt, who has Dutch nationality, obtained a bachelor’s degree in commercial economics at the HEAO school for higher education and a master’s degree in marketing from the Netherlands Institute of Marketing (NIMA).

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

For further information

Constantijn van Rietschoten

Chief Communications Officer

Tel. 85

 

Please open the link below for the press release:



EN
20/12/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fagron SA

Robert Jan Vos ... (+2)
  • Robert Jan Vos
  • Usama Tariq
Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Michiel Declercq
  • Thibault Leneeuw
  • Wim Lewi

Morning Notes : BAR BB, COFB BB, FAGR BB, GLPG NA, IBAB BB, DEME BB, N...

: BAR BB, COFB BB, FAGR BB, GLPG NA, IBAB BB, DEME BB, NXFIL NA, ENRGY BB

 PRESS RELEASE

Fagron versnelt globale expansie met twee strategische overnames en ve...

Fagron versnelt globale expansie met twee strategische overnames en verkrijgt belangrijke licentie in Noord Amerika Gereglementeerde informatie - voorkennisNazareth (België)/Rotterdam (Nederland), 19 december 2025 – 7:00 AM CET          Fagron versnelt globale expansie met twee strategische overnames en verkrijgt belangrijke licentie in Noord Amerika Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, is verheugd om twee strategische overnames aan te kondigen. Deze overnames helpen om onze globale aanwezigheid verder te versterken en capaciteiten te diversifiëren...

 PRESS RELEASE

Fagron accelerates global expansion with two strategic acquisitions an...

Fagron accelerates global expansion with two strategic acquisitions and a key North American licensing milestone Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 19 December 2025 – 7:00 AM CET Fagron accelerates global expansion with two strategic acquisitions and a key North American licensing milestone Fagron, the leading global player in pharmaceutical compounding, is pleased to announce two strategic acquisitions that further strengthen its global footprint and diversify its capabilities. These transactions include Amber Compounding Pharmacy, a...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Colruyt: Only 5 stores left to divest in France. EVS: Lower end of the range becomes the base case, on longer lead times. Fagron: Two EMEA acquisitions and California license for FSS. Kinepolis: “Wicked” achieves solid box office. OCI: Divesting Rotterdam ammonia terminal for €290m. Prosus: 1HFY26 results – on track

ResearchPool Subscriptions

Get the most out of your insights

Get in touch